Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
Kymera Therapeutics announced new preclinical data for KT-579, an oral IRF5 degrader showing disease-modifying effects in lupus models by targeting multiple inflammatory pathways. The ongoing Phase 1 trial in healthy volunteers aims to assess safety and biological activity, with results anticipated in the second half of 2026. Success could pave the…